FDA.reportPublic FDA data

2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]

RxCUI
2593419
RxNorm name
2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]
Display name
2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]
Full name
2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:38:48

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761090Takhzyrolanadelumab-flyo351(a)Disc2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8Takhzyro 300 MG in 2 ML Prefilled Syringe [PSN] · 2 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] [SBD] · Takhzyro 150 MG/ML per 2 ML Prefilled Syringe [SY] · Takhzyro 300 MG per 2 ML Prefilled Syringe [SY]414These highlights do not include all the information needed to use TAKHZYRO ® safely and effectively. See full prescribing information for TAKHZYRO ® . TAKHZYRO ® (lanadelumab-flyo) injection, for subcutaneous use Initial U.S. Approval: 201820250228